An innovative mathematical analysis of routine MRI scans in patients with glioblastoma using DoctorEye

Improving the initial diagnosis and the assessment of response to treatment in malignant gliomas, while avoiding invasive methods as much as justifiable, is one major aspect actual research is focusing on. Imaging studies are used to calculate tumor volume and define vital, necrotic and cystic areas within a tumor. Though the visual interpretation of magnetic resonance (MR) images is based on qualitative observation of variation in signal intensity, a correlation of signal intensities with histological features of a tumor is not possible. Better methods are needed for a reliable interpretation of follow-up studies in single patients. Histograms of signal intensities might serve as a method adding quantitative data to the description of a tumor. Using DoctorEye software, tumors can be easily rendered and histograms of the signal intensities within a tumor as well as mean and median signal intensities are possible to calculate. Our results in glioblastoma suggest that these histograms are an innovative method of gaining new tumor-specific information without performing additional investigations in a patient. It can be an additional diagnostic tool in differentiating various intracranial lesions from each other, as well as in assessing response to treatment or progression of malignant glioma.

[1]  M. Tsiknakis,et al.  The "Oncosimulator": a multilevel, clinically oriented simulation system of tumor growth and organism response to therapeutic schemes. Towards the clinical evaluation of in silico oncology , 2007, 2007 29th Annual International Conference of the IEEE Engineering in Medicine and Biology Society.

[2]  Thomas S. Deisboeck,et al.  Computational modeling of brain tumors: discrete, continuum or hybrid? , 2008 .

[3]  Vangelis Sakkalis,et al.  DoctorEye: A multifunctional open platform for fast annotation and visualization of tumors in medical images , 2009, 2009 Annual International Conference of the IEEE Engineering in Medicine and Biology Society.

[4]  Nikolaos K. Uzunoglu,et al.  A spatiotemporal, patient individualized simulation model of solid tumor response to chemotherapy in vivo: the paradigm of glioblastoma multiforme treated by temozolomide , 2006, IEEE Transactions on Biomedical Engineering.

[5]  Albert Lai,et al.  Apparent diffusion coefficient histogram analysis stratifies progression-free and overall survival in patients with recurrent GBM treated with bevacizumab: a multi-center study , 2012, Journal of Neuro-Oncology.

[6]  A. Brandes,et al.  MGMT promoter methylation status can predict the incidence and outcome of pseudoprogression after concomitant radiochemotherapy in newly diagnosed glioblastoma patients. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[7]  M. Platten,et al.  Neuroradiologische Responsekriterien bei malignen Gliomen , 2010, Der Nervenarzt.

[8]  M. Rosenthal,et al.  Imaging modalities in high-grade gliomas: Pseudoprogression, recurrence, or necrosis? , 2012, Journal of Clinical Neuroscience.

[9]  Bart Neyns,et al.  Pseudoprogression after radiotherapy with concurrent temozolomide for high-grade glioma: clinical observations and working recommendations. , 2009, Surgical neurology.

[10]  Dieta Brandsma,et al.  Clinical features, mechanisms, and management of pseudoprogression in malignant gliomas. , 2008, The Lancet. Oncology.

[11]  R. Luukkonen,et al.  Is the signal intensity of cerebrospinal fluid constant? Intensity measurements with high and low field magnetic resonance imagers. , 1993, Magnetic resonance imaging.

[12]  Zhihui Wang,et al.  Multiscale agent-based cancer modeling , 2009, Journal of mathematical biology.

[13]  J. Uhm Updated Response Assessment Criteria for High-Grade Gliomas: Response Assessment in Neuro-Oncology Working Group , 2010 .

[14]  L Leon Chen,et al.  An agent-based model identifies MRI regions of probable tumor invasion in a patient with glioblastoma , 2010, Physics in medicine and biology.

[15]  T. Cascino,et al.  Response criteria for phase II studies of supratentorial malignant glioma. , 1990, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[16]  Maria I. Argyropoulou,et al.  Glioma recurrence versus radiation necrosis: accuracy of current imaging modalities , 2009, Journal of Neuro-Oncology.